Physician profile
Kelson Figaro
NPI 1831128750
$1,094.69
in general payments reported to CMS, 2019-2025
18 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $237 · 2021: $46.20 · 2022: $15.66 · 2023: $89.60 · 2024: $95.39 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437 · Education: $26.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.21 |
| Education | $26.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $221.96 | 2025 | Nuplazid |
| Lilly USA, LLC | $185.56 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.33 | 2019-2023 | |
| Novo Nordisk INC | $120.69 | 2019-2024 | Ozempic, Rybelsus |
| Philips North America LLC | $94.41 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $78.05 | 2024-2025 | Rexulti |
| Pfizer INC. | $41.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $34.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.54 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.43 | 2020 | |
| Abbott Laboratories | $19.89 | 2023 | Freestyle Libre 2 |
| Abbvie INC. | $19.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.66 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.35 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.71 | 2020 | |
| Merck Sharp & Dohme LLC | $11.34 | 2020 | |
| Novartis Pharmaceuticals Corporation | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelson Figaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.